{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-056909","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.753211+00:00","generated_at":"2026-05-18T23:12:11.947279+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nektar’s rezpegaldesleukin meets primary & key secondary endpoints in Phase 2b atopic dermatitis trial","bullets":["REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).","EASI-75 achieved by 42-46% of rezpegaldesleukin patients vs 17% placebo; high dose also significant on EASI-90 (25% vs 9%).","Itch NRS (≥4-point reduction) 42% high dose, 35% middle dose vs 16% placebo; vIGA-AD 0/1 significant for q2w arms.","Safety profile consistent: injection site reactions (69.7%) mostly mild/moderate; no increased conjunctivitis, oral ulcers, or infections.","On-target Treg proliferation up to 6-fold; full 52-week data expected early 2026, alopecia areata top-line Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-056909","json":"https://secwatch.observer/filing/0001213900-25-056909.json","markdown":"https://secwatch.observer/filing/0001213900-25-056909.md","text":"https://secwatch.observer/filing/0001213900-25-056909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/0001213900-25-056909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/ea0246672-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:12:11.947279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}